Gene editing Archives

News and Trends 14 Jan 2020

Update: Horizon Discovery to Offer Partners Precise CRISPR Gene Editing

Update (14/01/20): Horizon Discovery will offer partners access to a precise version of CRISPR gene editing technology it has licensed from researchers at Rutgers University in the US. After a year of research and development, the UK biotech has incorporated the base-editing technique into its drug discovery platform and will use it to develop better […]

January 14, 2020 - 3 minutesmins - By Jonathan Smith

More News! 9 Oct 2019

Novo Nordisk and Bluebird Bio to Treat Hemophilia with Gene Editing

The Danish big pharma Novo Nordisk has joined forces with the US gene therapy company bluebird bio to develop next-generation gene editing treatments for hemophilia. The collaboration will last for three years and has the goal of developing a gene therapy that can permanently treat hemophilia A, a genetic disease causing uncontrolled bleeding. Novo Nordisk […]

October 9, 2019 - 1 minutemin - By Jonathan Smith

In Depth 11 Feb 2019

CRISPR: One Patent to Rule Them All

The gene editing tool CRISPR-Cas9 has revolutionized research in biology. With several parties fighting for the rights to the technology’s intellectual property, how difficult is it for third parties to access this coveted technology? The CRISPR patent dispute is quite unique. While universities usually work together to disseminate innovation and knowledge, in the CRISPR case […]

February 11, 2019 - 5 minutesmins - By Timothé Cynober

Best in Biotech 28 Jan 2019

5 Real-Life Technologies Where Biotech Meets Science Fiction

From genetic engineering to synthetic food and immortality, biotech is getting surprisingly close to recreating science fiction in real life. Science fiction is always a step ahead of real-life science. The genre imagined space travel, wireless communication and virtual reality years before they became a reality. In fact, sci-fi has coined some scientific terms […]

January 28, 2019 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Aug 2018

UK Biotech Raises €73M to Target DNA Repair in Treating Cancer

Artios Pharma completed a €73M (£65M) Series B financing round to develop cancer treatments that target DNA repair mechanisms. Cancer occurs when cells in part of the body start dividing uncontrollably as a result of damaged or mutated DNA. In collaboration with Cancer Research UK, Artios Pharma is developing cancer treatments that inhibit proteins involved […]

August 10, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 16 Jul 2018

CRISPR-Cas9 Shown to Cause Previously Unseen DNA Damage

Researchers at the Wellcome Trust Sanger Institute in the UK have found that gene editing with CRISPR-Cas9 can cause significantly more off-target damage to the DNA than previously thought. Published today in Nature Biotechnology, the study is the first to look at unexpected DNA changes caused by CRISPR across large regions of the genome. […]

July 16, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 28 Jun 2018

The Race to Get CRISPR to the Clinic: Hope Versus Hype

In 2016, German pharma giant Bayer took a bold step and decided to partner with CRISPR Therapeutics to form a company that could join the race to be first into the clinic with a CRISPR therapy. Peter Nell worked at Bayer for many years and was one of the founding team of Casebia Therapeutics. Now […]

June 28, 2018 - 7 minutesmins - By Helen Albert

News and Trends 21 Jun 2018

Gene Editing Could Cut the Cost of One of the Most Expensive Animal Diseases in the World

Researchers at the University of Edinburgh have genetically engineered pigs that are resistant to a common disease that has exorbitant costs to the livestock industry. Researchers at the University of Edinburgh, in collaboration with the animal genetics company Genus, have produced pigs that are resistant to one of the most costly animal diseases in the […]

June 21, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 1 Jun 2018

FDA Puts Clinical Trial for CRISPR Therapy on Hold

The FDA has put a hold on CRISPR Therapeutics’ planned Phase I/II trial testing a CRISPR gene-editing therapy in patients with sickle cell disease, which will likely delay the use of CRISPR-based therapies in humans. CRISPR Therapeutics, headquartered in Basel, Switzerland, and its partner Vertex Pharmaceuticals will have to postpone their plans to start a Phase I/II trial […]

June 1, 2018 - 2 minutesmins - By Alexander Burik

More News! 17 May 2018

After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering

Cellectis spin-off Calyxt has launched a €41M follow-on round after settling the lawsuit it recently brought against Bayer CropScience, for breach of a license agreement for access to patents for its TALEN technology. The French biotech Cellectis owns 79.1% of the ag biotech’s outstanding shares. Cellectis is well-known for its gene editing tool TALEN. However, while it focuses […]

May 17, 2018 - 2 minutesmins - By Helen Albert

In Depth 13 Mar 2018

The Most Important Battle in Gene Editing: CRISPR versus TALEN

Despite all the hype, CRISPR is still not in the clinic as a standalone therapy or part of another. So where is it in biotech? CRISPR needs no introduction. Since the gene editing technology first entered the spotlight in 2012 with the promise of revolutionizing gene editing, it has made headlines as the subject of a furious […]

March 13, 2018 - 6 minutesmins - By Editorial Team

News and Trends 16 Feb 2018

French Biotech Gets a CRISPR Patent for CAR-T Research

Update (16/02/2018): On top of the European patent it got last July, Cellectis now also has two US patents to use CRISPR technology to make CAR-T cells. Cellectis has said it will offer licenses to companies that want to use CRISPR gene editing in T cells. Not just for inserting CAR antigens, but also other editions […]

February 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us